Cargando…
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
Immunotherapy using PD-1 and CTLA4 inhibitors to stimulate T cell immunity has achieved significant clinical success. However, only a portion of patients benefit from T cell-based immunotherapy. Macrophages, the most abundant type of innate immune cells in the body, play an important role in elimina...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009010/ https://www.ncbi.nlm.nih.gov/pubmed/35418166 http://dx.doi.org/10.1186/s40364-022-00373-5 |